139 related articles for article (PubMed ID: 37201877)
1. Free-Fatty Acid Receptor-4 (FFA4/GPR120) differentially regulates migration, invasion, proliferation and tumor growth of papillary renal cell carcinoma cells.
Karmokar PF; Moniri NH
Biochem Pharmacol; 2023 Jul; 213():115590. PubMed ID: 37201877
[TBL] [Abstract][Full Text] [Related]
2. Free-fatty acid receptor-1 (FFA1/GPR40) promotes papillary RCC proliferation and tumor growth via Src/PI3K/AKT/NF-κB but suppresses migration by inhibition of EGFR, ERK1/2, STAT3 and EMT.
Karmokar PF; Moniri NH
Cancer Cell Int; 2023 Jun; 23(1):126. PubMed ID: 37355607
[TBL] [Abstract][Full Text] [Related]
3. Characterization of genetically defined sporadic and hereditary type 1 papillary renal cell carcinoma cell lines.
Yang Y; Ricketts CJ; Vocke CD; Killian JK; Padilla-Nash HM; Lang M; Wei D; Lee YH; Wangsa D; Sourbier C; Meltzer PS; Ried T; Merino MJ; Metwalli AR; Ball MW; Srinivasan R; Linehan WM
Genes Chromosomes Cancer; 2021 Jun; 60(6):434-446. PubMed ID: 33527590
[TBL] [Abstract][Full Text] [Related]
4. Carboxy-Terminal Phosphoregulation of the Long Splice Isoform of Free-Fatty Acid Receptor-4 Mediates
Senatorov IS; Cheshmehkani A; Burns RN; Singh K; Moniri NH
Mol Pharmacol; 2020 May; 97(5):304-313. PubMed ID: 32132133
[TBL] [Abstract][Full Text] [Related]
5. ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma.
Tanaka K; Kandori S; Sakka S; Nitta S; Tanuma K; Shiga M; Nagumo Y; Negoro H; Kojima T; Mathis BJ; Shimazui T; Watanabe M; Sato TA; Miyamoto T; Matsuzaka T; Shimano H; Nishiyama H
Oncol Rep; 2022 Feb; 47(2):. PubMed ID: 34841437
[TBL] [Abstract][Full Text] [Related]
6. Endothelin axis expression is markedly different in the two main subtypes of renal cell carcinoma.
Douglas ML; Richardson MM; Nicol DL
Cancer; 2004 May; 100(10):2118-24. PubMed ID: 15139053
[TBL] [Abstract][Full Text] [Related]
7. Impact of histologic subtype and sarcomatoid transformation on metastasis in renal cell carcinoma: a single institute experience in 149 patients.
Tirumani SH; Souza D; Krajewski KM; Jagannathan JP; Ramaiya NH; Shinagare AB
Abdom Radiol (NY); 2016 Feb; 41(2):295-302. PubMed ID: 26867911
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic and prognostic tissuemarkers in clear cell and papillary renal cell carcinoma.
Kroeze SG; Bijenhof AM; Bosch JL; Jans JJ
Cancer Biomark; 2010; 7(6):261-8. PubMed ID: 21694464
[TBL] [Abstract][Full Text] [Related]
9. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
[TBL] [Abstract][Full Text] [Related]
10. The knockdown of the mediator complex subunit MED30 suppresses the proliferation and migration of renal cell carcinoma cells.
Syring I; Weiten R; Müller T; Schmidt D; Steiner S; Müller SC; Kristiansen G; Ellinger J
Ann Diagn Pathol; 2018 Jun; 34():18-26. PubMed ID: 29661722
[TBL] [Abstract][Full Text] [Related]
11. Outcome of papillary versus clear cell renal cell carcinoma varies significantly in non-metastatic disease.
Wagener N; Edelmann D; Benner A; Zigeuner R; Borgmann H; Wolff I; Krabbe LM; Musquera M; Dell'Oglio P; Capitanio U; Klatte T; Cindolo L; May M; Brookman-May SD;
PLoS One; 2017; 12(9):e0184173. PubMed ID: 28934212
[TBL] [Abstract][Full Text] [Related]
12. Characterization of papillary and clear cell renal cell carcinoma through imaging mass cytometry reveals distinct immunologic profiles.
Govindarajan A; Salgia NJ; Li H; Castro DV; Mirzapoiazova T; Armstrong B; Zhao D; Mercier BD; Dizman N; Chawla N; Zengin Z; Meza L; Tripathi N; Sayegh N; Chehrazi-Raffle A; Tripathi A; Pal SK
Front Immunol; 2023; 14():1182581. PubMed ID: 37638025
[TBL] [Abstract][Full Text] [Related]
13. Genomic profiling of renal cell carcinoma in patients with end-stage renal disease.
Inoue T; Matsuura K; Yoshimoto T; Nguyen LT; Tsukamoto Y; Nakada C; Hijiya N; Narimatsu T; Nomura T; Sato F; Nagashima Y; Kashima K; Hatakeyama S; Ohyama C; Numakura K; Habuchi T; Nakagawa M; Seto M; Mimata H; Moriyama M
Cancer Sci; 2012 Mar; 103(3):569-76. PubMed ID: 22145865
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of HSP 90 is associated with potent anti-tumor activity in Papillary Renal Cell Carcinoma.
Pahwa R; Dubhashi J; Singh A; Jailwala P; Lobanov A; Thomas CJ; Ceribelli M; Wilson K; Ricketts CJ; Vocke CD; Wells C; Bottaro DP; Linehan WM; Neckers L; Srinivasan R
J Exp Clin Cancer Res; 2022 Jun; 41(1):208. PubMed ID: 35754026
[TBL] [Abstract][Full Text] [Related]
15. MicroRNA profiles classify papillary renal cell carcinoma subtypes.
Wach S; Nolte E; Theil A; Stöhr C; T Rau T; Hartmann A; Ekici A; Keck B; Taubert H; Wullich B
Br J Cancer; 2013 Aug; 109(3):714-22. PubMed ID: 23799849
[TBL] [Abstract][Full Text] [Related]
16. A novel molecular signature identifies mixed subtypes in renal cell carcinoma with poor prognosis and independent response to immunotherapy.
Büttner FA; Winter S; Stühler V; Rausch S; Hennenlotter J; Füssel S; Zastrow S; Meinhardt M; Toma M; Jerónimo C; Henrique R; Miranda-Gonçalves V; Kröger N; Ribback S; Hartmann A; Agaimy A; Stöhr C; Polifka I; Fend F; Scharpf M; Comperat E; Wasinger G; Moch H; Stenzl A; Gerlinger M; Bedke J; Schwab M; Schaeffeler E
Genome Med; 2022 Sep; 14(1):105. PubMed ID: 36109798
[TBL] [Abstract][Full Text] [Related]
17. Omega-3 fatty acids and other FFA4 agonists inhibit growth factor signaling in human prostate cancer cells.
Liu Z; Hopkins MM; Zhang Z; Quisenberry CB; Fix LC; Galvan BM; Meier KE
J Pharmacol Exp Ther; 2015 Feb; 352(2):380-94. PubMed ID: 25491146
[TBL] [Abstract][Full Text] [Related]
18. Low expression of PDK1 inhibits renal cell carcinoma cell proliferation, migration, invasion and epithelial mesenchymal transition through inhibition of the PI3K-PDK1-Akt pathway.
Zhou WM; Wu GL; Huang J; Li JG; Hao C; He QM; Chen XD; Wang GX; Tu XH
Cell Signal; 2019 Apr; 56():1-14. PubMed ID: 30465826
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic signaling of the free-fatty acid receptors FFA1 and FFA4 in human breast carcinoma cells.
Karmokar PF; Moniri NH
Biochem Pharmacol; 2022 Dec; 206():115328. PubMed ID: 36309079
[TBL] [Abstract][Full Text] [Related]
20. Comparison of type I and II papillary renal cell carcinoma (RCC) and clear cell RCC.
Waldert M; Haitel A; Marberger M; Katzenbeisser D; Ozsoy M; Stadler E; Remzi M
BJU Int; 2008 Nov; 102(10):1381-4. PubMed ID: 18782311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
